Approval On December 19, 2017, the FDA approved Merck & Co. and Pfizer's new diabetes drug, Steglatro, and its two combination versions, Steglujan and Segluromet.  These drugs are classified as sodium/glucose cotransporter 2 (SGLT2) inhibitors, and will be available this coming January. Steglatro consists of ertugliflozin, while Steglujan … [Read more...]